Brief: Oncoquest Receives "Notice Of Allowance" For Patent Protection Of Administration Schedule Of Oregovomab And Chemotherapy For Stage III-IV Ovarian Cancer Patients
25/09/2019 12:14
Sept 25 (Reuters) - Quest Pharmatech Inc QPT.V :
* ONCOQUEST RECEIVES "NOTICE OF ALLOWANCE" FOR PATENT
PROTECTION
OF THE ADMINISTRATION SCHEDULE OF OREGOVOMAB AND CHEMOTHERAPY
FOR STAGE III-IV OVARIAN CANCER PATIENTS
* QUEST PHARMATECH - CO IS CURRENTLY PLANNING TO LAUNCH A
PHASE 3
TRIAL FOR OREGOVOMAB IN Q1 2020
Source text for Eikon: ID:nPn1gxXXHa
Further company coverage: QPT.V
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Quest PharmaTech
See all newsBrief: Quest Pharmatech Announces Change Of Chief Executive Officer
Brief: Quest Pharmatech Provides Product Development Update
Brief: Quest PharmaTech Clarifies Agreement in Principle with OQP Bio
Brief: Quest Pharmatech Provides Corporate Update
Brief: Quest PharmaTech Announces Sale Of Bioceltran Investment And Return Of Photodynamic Therapy Technology License